Published in PLoS One on August 12, 2013
Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis. PLoS One (2014) 1.07
Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice. Eur J Immunol (2016) 0.84
Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med (2015) 0.84
Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther (2015) 0.80
The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease. J Immunol Res (2014) 0.79
IgG, IgM, and IgA antinuclear antibodies in discoid and systemic lupus erythematosus patients. ScientificWorldJournal (2014) 0.77
Analyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy. Arthritis Res Ther (2015) 0.75
The Level of IgA Antibodies to Endothelial Cells Correlates with Histological Evidence of Disease Activity in Patients with Lupus Nephritis. PLoS One (2016) 0.75
C4 Deficiency is a predisposing factor for Streptococcus pneumoniae-induced autoantibody production. J Immunol (2014) 0.75
Establishing a tree shrew model of systemic lupus erythematosus and cell transplantation treatment. Stem Cell Res Ther (2016) 0.75
Binding of estrogen receptors to switch sites and regulatory elements in the immunoglobulin heavy chain locus of activated B cells suggests a direct influence of estrogen on antibody expression. Mol Immunol (2016) 0.75
Concomitance of IgM and IgG anti-dsDNA Antibodies Does Not Appear to Associate to Active Lupus Nephritis. Open Rheumatol J (2013) 0.75
Ginsenoside Rh1 Improves the Effect of Dexamethasone on Autoantibodies Production and Lymphoproliferation in MRL/lpr Mice. Evid Based Complement Alternat Med (2015) 0.75
Is Tolerance Broken in Autoimmunity? Clin Med Insights Pathol (2017) 0.75
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 18.52
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
Polymyositis and dermatomyositis (second of two parts). N Engl J Med (1975) 7.26
Purification of the centromere-specific protein CENP-A and demonstration that it is a distinctive histone. Proc Natl Acad Sci U S A (1991) 3.55
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum (1990) 3.37
Antibodies to DNA. N Engl J Med (1998) 3.04
Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum (1979) 2.23
Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A (2000) 2.03
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int Immunol (1994) 1.43
Prevention of relapses in systemic lupus erythematosus. Lancet (1995) 1.33
Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum (2005) 1.23
Complement activation by (auto-) antibodies. Mol Immunol (2011) 1.22
SLE diagnosis and treatment: when early is early. Autoimmun Rev (2010) 1.13
Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus (2004) 1.11
Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus (2011) 1.11
Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum (1994) 1.09
The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis (1997) 1.05
IgM antibodies against dsDNA in SLE. Clin Rev Allergy Immunol (2008) 1.04
Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol (2012) 1.01
IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group. Rheumatol Int (1998) 1.00
Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun (2004) 0.98
Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol (2012) 0.98
Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus (2003) 0.96
A longitudinal study of high and low avidity antibodies to double-stranded DNA in systemic lupus erythematosus. Arthritis Rheum (1985) 0.95
Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev (2011) 0.91
Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum (2005) 0.91
Antibodies to dsDNA and ssDNA in the immunoglobulin classes IgG and IgM: prognostic value in the course of SLE. Z Rheumatol (1985) 0.90
Anti-dsDNA antibodies in Brazilian patients of mainly African descent with systemic lupus erythematosus: lack of association with lupus nephritis. Clin Rheumatol (2009) 0.88
Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum (2003) 0.87
Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol (2011) 0.86
IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis (2010) 0.86
Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus (2012) 0.85
IgA anti-dsDNA antibodies in systemic lupus erythematosus: occurrence, incidence and association with clinical and laboratory variables of disease activity. J Rheumatol (1993) 0.85
Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group. Rheumatol Int (1998) 0.84
Antigen specificity of antihistone antibodies in systemic sclerosis. Ann Rheum Dis (1998) 0.84
Evaluation of a new automated enzyme fluoroimmunoassay using recombinant plasmid dsDNA for the detection of anti-dsDNA antibodies in SLE. J Clin Lab Anal (2002) 0.78
Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with systemic lupus erythematosus and other autoimmune systemic diseases. Ann N Y Acad Sci (2007) 0.77
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol (2011) 2.45
Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol (2012) 2.43
Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum (2002) 2.23
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) (2003) 2.05
Autophagy in human health and disease. N Engl J Med (2013) 2.04
Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03
Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: prevalence and clinical value. Autoimmunity (2008) 1.90
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis (2012) 1.85
Gout: why is this curable disease so seldom cured? Ann Rheum Dis (2012) 1.84
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant (2008) 1.77
Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci (2005) 1.63
Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56
Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev (2012) 1.51
The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev (2011) 1.47
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol (2009) 1.44
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
Autoantibody profiling of patients with autoimmune thyroid disease using a new multiplexed immunoassay method. Clin Chem Lab Med (2006) 1.39
Retracted Drug-induced lupus erythematosus. Autoimmunity (2005) 1.31
Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol (2002) 1.26
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci (2007) 1.26
Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep (2013) 1.25
Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev (2011) 1.25
Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med (2006) 1.24
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol (2005) 1.16
Resistant Behçet disease responsive to anakinra. Ann Intern Med (2008) 1.15
Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci (2007) 1.15
OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol (2011) 1.14
SLE diagnosis and treatment: when early is early. Autoimmun Rev (2010) 1.13
PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun (2010) 1.13
Environment and systemic lupus erythematosus: an overview. Autoimmunity (2005) 1.12
Anti-Mi-2 antibodies. Autoimmunity (2005) 1.10
Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev (2011) 1.10
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol (2006) 1.09
Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol (2006) 1.07
Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly (2010) 1.06
Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev (2010) 1.05
Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05
Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol (2013) 1.05
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) (2011) 1.04
Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum (2004) 1.04
Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: a systematic review and meta-analysis. Autoimmun Rev (2012) 1.04
Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) (2010) 1.04
High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal (2005) 1.03
Treatment strategy in fibromyalgia syndrome: where are we now? Semin Arthritis Rheum (2007) 1.03
Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev (2011) 1.03
Estrogens in pregnancy and systemic lupus erythematosus. Ann N Y Acad Sci (2006) 1.02
Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine (2010) 1.02
Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol (2006) 1.01
The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum (2008) 1.01
Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev (2007) 1.00
Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. J Clin Immunol (2012) 1.00
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis (2011) 1.00
Blau syndrome, clinical and genetic aspects. Autoimmun Rev (2012) 0.99
SERPINB3, apoptosis and autoimmunity. Autoimmun Rev (2009) 0.99
Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev (2006) 0.98
Autoantibodies and prediction of reproductive failure. Am J Reprod Immunol (2006) 0.98
The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. Int J Rheum Dis (2013) 0.98
Chronic fatigue syndrome: characteristics and possible causes for its pathogenesis. Isr Med Assoc J (2008) 0.98
Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol (2012) 0.98